| abstract |
The present invention relates to novel immunological reagents, more specifically, therapeutic antibody reagents for the prevention and treatment of amyloidogenic disease (e.g., Alzheimer's disease). The invention is based at least on the identification and characterization of two monoclonal antibodies that specifically bind to Ab peptide and effectively reduce plaque load and / or reduce neurotic dystrophy associated with amyloidogenic disorders. SHE |